Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Biomarker Study for Predicting the Response of Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer Based on Circulating Tumor DNA and Homologous Recombination Deficiency Analysis

NCT05965557 is registered in ClinicalTrials.gov with Geneplus-Beijing Co. Ltd. as lead sponsor.

NCT NCT05965557
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05965557 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Biomarker Study for Predicting the Response of Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer Based on Circulating Tumor DNA and Homologous Recombination Deficiency Analysis
Lead sponsor
Geneplus-Beijing Co. Ltd.
Phase
Observational
Overall status
Recruiting
Start date
June 19, 2023
Completion date
December 31, 2027
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer